Experience of padma 28 in multiple sclerosis

Korwin-Piotrowska, T; Nocoń, D; Stańkowska-Chomicz, A; Starkiewicz, A.; Wójcicki, J; Samochowiec, L

doi:10.1002/ptr.2650060306

Cited by 17 publications

(22 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…2 open trials in 44 patients with viral hepatitis B showed improved serological status and biochemical parameters [26,27]. 1 RCT in patients with progressive multiple sclerosis found an improvement in 44% and a deterioration in 12% of the verum group compared to zero improvement but 40% deterioration in patients with symptomatic treatment (analgesics, spasmolytics) alone over 1 year of treatment [28]. 1 comparative study (comparison of treatment with another multi-herbal formula) in 23 patients with duodenal peptic ulcer showed complete remission in 43.5% of the patients and improvement in another 43.5% treated with the phytotherapeutic, as assessed by endoscopy [29].…”

Section: Resultsmentioning

confidence: 99%

“…1 randomized trial in MS had an evidence level of II [28]; the other studies in inflammatory and autoimmune diseases were not randomized and had evidence levels of III-2 to IV. Low Jadad scores were mainly found in older studies and due to lacking data on the method of randomization, blinding, and dropouts and withdrawals.…”

Section: Resultsmentioning

confidence: 99%

“…Many studies in these indications were done in Poland [39]. They generally date back before the implementation of International Conference on Harmonization (ICH) guidelines and are thus of a quite lower quality than today's standards and, except for the study in multiple sclerosis [28], were not placebo-controlled. In Poland, the preparation has been used since decades also in pediatric patients.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Clinical Studies on the Efficacy and Safety of Padma 28, a Complex Herbal Formulation from Tibetan Medicine: An Overview

Vennos¹,

Melzer

Saller

2013

Complement Med Res

View full text Add to dashboard Cite

Background: Padma 28 is an herbal formula from Tibetan Medicine, which since 35 years has been registered in Switzerland as a drug for the symptoms of circulatory disorders. Over this time, a large body of scientific literature has accumulated. The aim of this article was to give an overview of the clinical studies. Methods: A systematic literature search was done in PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials (CCRCT). The clinical trials found were assessed regarding fields of application, efficacy, and safety, as well as methodological quality and level of evidence. Results: 29 trials (1 meta-analysis, 21 controlled trials, 7 open trials) and 3 retrospective case studies were found. They deal with different indications and include a total of 1,704 verum (of these, 697 children), 333 placebo, and 394 untreated or healthy patients. Dropouts and withdrawals were 2.5 and 3.5 times higher in the placebo than in the verum group, respectively. The highest level of evidence for the use of Padma 28 was found in the indication of intermittent claudication (11 trials). Indications of efficacy were also found in other vascular (6 trials) and different inflammatory diseases (12 trials). Conclusions: The results suggest a favorable safety profile for Padma 28, also in the children examined (41% of the study population). Furthermore, the results show a broad field of applications. According to clinical evidence, Padma 28 has shown to be a safe and effective symptomatic treatment option for atherosclerosis-related diseases such as intermittent claudication. It also seems to have a potential for application in certain chronic inflammatory diseases such as recurrent respiratory tract infections, viral hepatitis, and multiple sclerosis. However, further randomized controlled trials (RCT) are needed to confirm these findings.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical Studies on the Efficacy and Safety of Padma 28, a Complex Herbal Formulation from Tibetan Medicine: An Overview

Vennos¹,

Melzer

Saller

2013

Complement Med Res

View full text Add to dashboard Cite

show abstract

“…There are limited scientific and clinical studies of Padma 28. It appears to have antioxidant and immunosuppressive effects [72,73]. In a study of mice with EAE, animals that consumed water that contained Padma 28 had longer survival times and decreased death rates [72].…”

Section: Padma 28mentioning

confidence: 98%

Current complementary and alternative therapies for multiple sclerosis

Bowling

Stewart

2003

Curr Treat Options Neurol

View full text Add to dashboard Cite

The use of complementary and alternative medicine (CAM) appears to be high in the general population and in patients with multiple sclerosis (MS). There are no diets or dietary supplements that are definitely effective in altering the disease course in MS. However, diets and dietary supplements that increase the intake of polyunsaturated fatty acids may produce mildly beneficial effects. Because these approaches are not definitely effective, they may be of limited interest to physicians and other conventional health providers. In contrast, for patients with MS, these interventions may be of considerable interest, because they may be mildly effective and are inexpensive and relatively safe. Vitamin D, ginkgo biloba, cannabinoids, and Padma 28 produce immunomodulatory actions and therapeutic effects in experimental autoimmune encephalomyelitis. However, for these compounds, there are not enough clinical trial data or safety information to support their use as disease-modifying therapies. The role of antioxidant compounds in MS is unclear. There is no evidence that vitamin B(12) supplementation or gluten-free diets are effective MS therapies. Conventional health providers can play an important role in the care of MS patients by being open to discuss CAM therapies and by providing objective MS-relevant CAM information.

show abstract

“…Eine Reihe von klinischen Studien und Anwendungsbeobachtungen hat die Wirkung von Padma 28 bei Patienten mit Claudicatio intermittens [1] und weiteren Formen von Durchblutungsstörungen wie Angina pectoris, Rekonvaleszenz nach ischämischem Hirnschlag und schlecht heilenden Wunden wie Ulcus cruris venosum erforscht [2][3][4]. Andere Studien dehnten das Anwendungsgebiet auf eine Reihe zusätzlicher Indikationen aus, etwa chronische Zahnpulpitis, Hepatitis B, Atemwegsinfekte, rheumatoide Arthritis und multiple Sklerose [5][6][7][8][9]. Allen Indikationsstellungen gemein ist der pathogenetische Hintergrund chronisch entzündlicher und autoimmun bedingter Prozesse.…”

Section: Introductionunclassified

Das anti-inflammatorische Potential von Padma 28 – Übersicht experimenteller Daten zur antiatherogenen Wirkung und Diskussion des Vielstoffkonzepts

Ueberall¹,

Fuchs

Vennos³

2006

Forsch Komplementärmed

View full text Add to dashboard Cite

Hintergrund: Das Tibetische Arzneimittel Padma 28 wird seit Jahrzehnten in Europa angewendet und hat sich besonders bei entzündlich und arteriosklerotisch bedingten Beschwerden als wirksam erwiesen. Neben klinischen Studien liegt eine grosse Anzahl von In-vitro- und Ex-vivo-Studien vor, die verschiedene Eigenschaften und biochemische Aktivitäten dieses komplex zusammengesetzten Pflanzenpräparates belegen. Fragestellung: Ziel ist es, anhand der vorliegenden Daten einen Überblick über das komplexe Wirkprofil von Padma 28 zu geben, die vorliegenden Erkenntnisse in Beziehung zur Entwicklung von Arteriosklerose zu setzen und anhand dessen das antiatherogene Potential von Padma 28 zu diskutieren. Methoden: Die publizierten wissenschaftlichen, nichtklinischen Originalarbeiten über Padma 28 wurden erfasst und gemäss den darin untersuchten Wirkmechanismen klassifiziert. Die Resultate werden in Beziehung zu den kurz dargestellten Vorgängen der Atherogenese gesetzt, wobei verschiedene Wirkmechanismen herausgearbeitet und besonderes Gewicht auf neuere Arbeiten gelegt wurde. Ergebnisse: Das vielschichtige Wirkprofil von Padma 28 umfasst vor allem direkte und indirekte anti-inflammatorische Wirkungen sowie weitere Kategorien von biochemischen Mechanismen. Diese lassen sich den komplexen Vorgängen der Atherogenese zuordnen. Schlussfolgerungen: Die beschriebenen Mechanismen stützen das therapeutische Anwendungsgebiet von Padma 28 – periphere Durchblutungsstörungen sowie Erkrankungen des chronisch entzündlichen Formenkreises. Auch lässt die Vielzahl der Wirkmechanismen sowie der Wirkorte einen ersten Schluss auf die konzeptionelle Formulierung dieses Vielstoffgemischs zu.

show abstract

Experience of padma 28 in multiple sclerosis

Cited by 17 publications

References 6 publications

Clinical Studies on the Efficacy and Safety of Padma 28, a Complex Herbal Formulation from Tibetan Medicine: An Overview

Clinical Studies on the Efficacy and Safety of Padma 28, a Complex Herbal Formulation from Tibetan Medicine: An Overview

Current complementary and alternative therapies for multiple sclerosis

Das anti-inflammatorische Potential von Padma 28 – Übersicht experimenteller Daten zur antiatherogenen Wirkung und Diskussion des Vielstoffkonzepts

Contact Info

Product

Resources

About